CD8A and hepatocellular carcinoma: The functionally detectable presence of M3 (271) specific CD8+ T cells in HCC patients makes M3 (271) a potential target for immunotherapy in these patients. CD8+ T cells that respond to both NY-ESO-1 and MAG-A3 antigens provide a theoretical basis for the use of a bivalent vaccine in HCC patients with tumors expressing both antigens.